Organic Electroluminescence Device and Novel Compound
A patent family: one line of work, grouped by real continuity rather than by a technology label
inferred from titles. 5 of these applications claim priority to application 16/201,984, filed Nov 27, 2018. A shared origin can cover several different claimed inventions, which is why members here may not share a title. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
| Patent | Title | Holder | Status | Expires | Time remaining | Confidence |
|---|---|---|---|---|---|---|
| US 10,249,832 | Organic Electroluminescence Device and Novel Compound In force · High confidence | Idemitsu Kosan Co., Ltd. | In force | High confidence | ||
| US 10,680,181 | Organic Electroluminescence Device and Novel Compound In force · Medium confidence | Idemitsu Kosan Co., Ltd. | In force | Medium confidence | ||
| US 10,658,594 | Organic Electroluminescence Device and Novel Compound In force · High confidence | Idemitsu Kosan Co., Ltd. | In force | High confidence | ||
| US 10,672,989 | Organic Electroluminescence Device and Novel Compound In force · High confidence | Idemitsu Kosan Co., Ltd. | In force | High confidence | ||
| US 12,262,634 | Organic Electroluminescence Device and Novel Compound In force · Medium confidence | Idemitsu Kosan Co., Ltd. | In force | Medium confidence | ||
| US 11,569,449 | Organic Electroluminescence Device and Novel Compound In force · Medium confidence | Idemitsu Kosan Co., Ltd. | In force | Medium confidence | ||
| US 11,557,730 | Organic Electroluminescence Device and Novel Compound In force · Medium confidence | Idemitsu Kosan Co., Ltd. | In force | Medium confidence |
7 of 7 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
Updated Nov 16, 2026 · includes USPTO assignment & status data published Nov 16, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.